The CD5 antigen is expressed on mature T cells and some B cells, but not on stem cells or other tissues. The product may be used to treat autoimmune diseases such as rheumatoid arthritis as well as T and B-cell malignancies. XOMA is evaluating several indications for clinical testing and is seeking partners for further development and commercialization. The product was developed using XOMA's patented targeted gelonin fusion technology, which is also available for licensing. XOMA and the Hyland Immuno Division of Baxter Healthcare are developing this systemic formulation of rBPI-21 for multiple indications.
Current work is directed at optimizing a formulation for clinical testing.
It has been initially formulated as an injectable product targeting systemic fungal infections. XOMA is currently completing the necessary preclinical work to support filing an IND, and is seeking partners for clinical development and commercialization of the product. Antiangiogenic compounds are in preclinical development with an initial focus on retinal disorders. XOMA is in discussions with potential partners. To listen to the live call, please go to the Web site at least 15 minutes prior to the start of the call to register, download and install any necessary audio software.